Fotodermatosis mediadas inmunológicamente

-A A +A
Artículo de revisión
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 29-44.

Fotodermatosis mediadas inmunológicamente

Immunologically mediated photodermatoses
Autor(es): 
Claudia Juliana Mariaca
julianamariaca@hotmail.com
Médica dermatóloga, Universidad Pontificia Bolivariana, Medellín, Colombia
Rodrigo Nuñez
Médico dermatólogo; profesor de Dermatología, Universidad Pontificia Bolivariana, Medellín, Colombia
Resumen: 

Las fotodermatosis son enfermedades de la piel inducidas o exacerbadas por la radiación electromagnética (radiación ultravioleta, luz visible) y se pueden dividir en cinco grupos: fotodermatosis mediadas inmunológicamente, fotodermatosis secundarias a agentes exógenos, fotodermatosis secundarias a agentes endógenos y enfermedades causadas por defecto en la reparación del ADN (genodermatosis). En este artículo, se revisa el primer grupo de fotodermatosis, las cuales incluyen la erupción solar polimorfa, el prurigo actínico, la dermatitis actínica crónica, la urticaria solar y la hidroa vacciniforme.

Palabras clave: 
fotosensibilidad, rayos ultravioleta, prurigo actínico, urticaria solar, hidroa vacciniforme.

Summary: 

Photodermatoses are skin diseases induced or exacerbated by the electromagnetic radiation (ultraviolet radiation, visible light and infrared radiation) and they can be divided into five groups: immunologically mediated photodermatoses, photodermatoses secondary to exogenous agents, photodermatoses secondary to endogenous agents and diseases caused by a defect in the reparation of DNA (genodermatoses). In this article, we will review the first group of photodermatoses, which includespolymorphous light eruption, actinic prurigo, chronic actinic dermatitis, solar urticarial and hydroa vacciniforme.

Key words: 
Photosensitivity disorders, ultraviolet rays, actinic prurigo, solar urticaria, hydroa vacciniforme, polymorphic light eruption.
PDF del articulo

Referencias

  1. Rizwan M, Reddick CL, Bundy C, Unsworth R, Richards HL, Rhodes LE. Photodermatoses: Environmentally induced conditions with high psychological impact. Photochem Photobiol Sci 2013;12:182-9.
  2. Choi D, Kannan S, Lim H. Evaluation of patients with photodermatoses. Dermatol Clin. 2014,32:267-75.
  3. Bylaite M, Grigaitiene J, Lapinskaite GS. Photodermatoses: Classification, evaluation and management. Br J Dermatol. 2009;161:61-8.
  4. Yashar SS, Lim HW. Classification and evaluation of photodermatoses. Dermatol Ther. 2003;16:1-7.
  5. De Argila D, Aguilera J, Sánchez J, García-Díez A. Study of idiopathic, exogenous photodermatoses. Part II: Photobiologic testing. Actas Dermosifiliogr. 2014;105:233-42. 
  6. De Argila D, Aguilera J, Sánchez J, García-Díez A. Study of idiopathic, exogenous photodermatoses. Part I: Pathophysiology and technical aspects of photobiologic studies. Actas Dermosifilogr. 2014;105:112-21.
  7. Lehmann P, Schwarz T. Photodermatoses: Diagnosis and treatment. Dtsch Arztebl Int. 2011;108:135-41.
  8. Gambichler T, Al-Muhhammadi R, Bomms S. Immunologically mediated photodermatoses. Am J Clin Dermatol. 2009;10:169-80.
  9. Trakatelli M, Charalampidis S, Novakovic LB. Photodermatoses with onset in the elderly. Br J Dermatol. 2009;161:69-77.
  10. Roelandts R. Diagnosis and treatment of solar urticaria. Dermatol Ther. 2003;16:52-6. 
  11. Morales N, Zapata F, Zuluaga MA, Mendoza N, Uribe MP, Jiménez SB. Fotodermatosis y terapia de desensibilización. Revista CES Medicina. 2012;26:29-41,
  12. Grossber AL. Update on pediatric photosensitivity disorders. Curr Opin Pediatr. 2013;25:474-9. 
  13. Stratigos AJ, Antoniou C, Katsambas AD. Polymorphous light eruption. J Eur Acad Dermatol Venereol. 2002;16:193-206.
  14. Gruber-Wackermagel A, Byrne SN, Wolf P. Polymorphous light eruption: Clinic aspects and pathogenesis. Dermatol Clin. 2014;32:315-34. 
  15. Wolf P, Byrne SN, Gruber-Wackernagel A. New insights into the mechanisms of polymorphic light eruption: Resistance to ultraviolet radiation induced immune suppression as an aetiological factor. Exp Dermatol.2009;18:350-6.
  16. Elmets CA, Cala CM, Xu H. Photoimmunology. Dermatol Clin. 2014;32:277-90.
  17. Lecha M. Idiopathic photodermatoses: Clinical, diagnostic and therapeutic aspects. Eur Acad Dermatol Venereol. 2001;15:499-505. 
  18. Lava SA, Simonetti GD, Ragazzi M, Guarino Gubler S, Bianchetti MG. Juvenile spring eruption: An outbreak report and systematic review of the literature. Br J Dermatol. 2013;168:1066-72.
  19. Ros AM. Solar purpura –an unusual manifestation of polymorphous light eruption. Photodermatol. 1988;5:47-8.
  20. Kalivas J, Kalivas L. Solar purpura appearing in a patient with polymorphous light eruption. Photodermatol Photoimmunol Photomed. 1995;11:31-2.
  21. Jansen CT, Karvonen J. Polymorphous light eruption. A seven-year follow-up evaluation of 114 patients. Arch Dermatol. 1984;120:862-5.
  22. Murphy GM, Hawk JL. The prevalence of antinuclear antibodies in patients with apparent polymorphic light eruption. Br J Dermatol. 1991;125:448-51.
  23. Petzelbauer P, Binder M, Nikolakis P, Ortel B, Honigsmann H. Severe sun sensitivity and the presence of antinuclear antibodies in patients with polymorphous light eruption-like lesions. A form fruste of photosensitive lupus erythematosus? J Am Acad Dermatol. 1992;26:68-74.
  24. Hasan T, Ranki A, Jansen CT, Karvonen J. Disease associations in polymorphous light eruption. A longterm follow-up study of 94 patients. Arch Dermatol. 1998;134:1081-5.
  25. Mastalier U, Kerl H, Wolf P. Clinical, laboratory, phototest and phototherapy findings in polymorphic light eruptions: A retrospective study of 133 patients. Eur J Dermatol. 1998;8:554-9.
  26. Tzaneva S, Volc-Platzer B, Kittler H, Honigsmann H, Tanew A. Antinuclear antibodies in patients with polymorphic light eruption: A long-term follow-up study. Br J Dermatol. 2008;158:1050-4.
  27. Stratigos AJ, Antoniou C, Katsambas AD. Polymorphous light eruption. J Eur Acad Dermatol Venerol. 2002;16:193-206. 
  28. Honigsmann H. Polymorphous light eruption. Photodermatol Photoimmunol Photomed. 2008;24:155-61.
  29. Patel DC, Bellaney GJ, Sedd PT, McGregor JM, Hawk JL. Efficacy of short-course oral prednisolone in polymorphic light eruption: A randomized controlled trial. Br J Dermatol. 2000;143:828-31.    
  30. Pareek A, Khopkar U, Sacchidanand S, Chandurkar N, Naik GS. Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: A randomized, double-blind, multicentric study. Indian J Dermatol Venerol Leprol. 2008;74:18-22.
  31. Rodríguez C, Marsol I. Antimalarials in dermatology: Mechanism of action, indications, and side effects. Actas Dermosifiliogr. 2014;105:243-52. 
  32. Wolf R, Wolf D, Ruocco V. Antimalarials: Unapproved uses or indications. Clin Dermatol. 2000;18:17-35. 
  33. Honigsmann H. Mechanisms of phototherapy and photochemotherapy for photodermatoses. Dermatol Ther. 2003;16:23-7.
  34. Caccialanza M, Percivalle S, Piccinno R, Brambilla R. Photoprotective activity of oral Polypodium leucotomos extract in 25 patients with idiopathic photodermatoses. Photodermatol Photoimmunol Photomed. 2007;23:46-7.
  35. Hanneman KK, Scull HM, Cooper KD, Baron ED. Effect of topical vitamin D analogue on in vivo contact sensitization. Arch Dermatol. 2006;142:1332-4.
  36. Valbuena MC, Muvdi S, Lim HW. Actinic prurigo. Dermatol Clin. 2014;32:335-44.
  37. Hojyo-Tomoka MT, Vega-Memije ME, Cortés-Franco R. Diagnosis and treatment of actinic prurigo. Dermatol Ther. 2003;16:40-4.
  38. Ferguson J. Diagnosis and treatment of the common idiopathic photodermatoses. Australas J Dermatol. 2003;44:90-6.
  39. Lane PR, Hogan DJ, Martel MJ, Reeder B, Irvine J. Actinic prurigo: Clinical features and prognosis. J Am Acad Dermatol. 1992;26:683-92.
  40. Torres-Álvarez B, Baranda L, Fuentes C, Delgado C, Santos-Martínez L, Portales-Pérez D, et al. An immunohistochemical study of UV-induced skin lesions in actinic prurigo. Resistance of Langerhans cells to UV light. Eur J Dermatol. 1998;8:24-8.
  41. Menage H du P, Vaughan RW, Baker CS, Page G, Proby CM, Breathbach SM, et al. HLADR4 may determine expression of actinic prurigo in British patients. J Invest Dermatol. 1996;106:362-7.
  42. Zuluaga-Salcedo S, Castillo-Vázquez M, Vega-Memije E, Arellano-Campos O, Rodríguez-Pérez JM, Pérez Hernández N, et al. Class I and class II major histocompatibility complex genes in Mexican patients with actinic prurigo. Br J Dermatol. 2007;156:1074-5.
  43. Suárez A, Valbuena MC, Rey M, Porras L. Association of HLA subtype DRB10407 in Colombian patients with actinic prurigo. Photodermatol Photoimmunol Photomed. 2006;22:55-8.
  44. Wiseman MC, Orr PH, Macdonald SM, Schroeder ML, Toole JW. Actinic prurigo: Clinical features and HLA associations in a Canadian Inuit population. J Am Acad Dermatol. 2001;44:952-6.
  45. Magaña M, Méndez Y, Rodríguez A, Mascott M. The conjunctivitis of solar (actinic) prurigo. Pediatr Dermatol. 2000;17:432-5.
  46. Vega-Memije ME, Mosqueda-Taylor A, Iriqoyen-Camacho ME. Actinic prurigo cheilitis: Clinic-pathologic analysis and therapeutic results in 116 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:83-91.
  47. Herrera-Geopfert R, Magaña M. Follicular cheilitis. A distinctive histopathologic finding in actinic prurigo. Am J Dermatopathol. 1995;17:357-61.
  48. Miranda AM, Ferrari TM, Werneck JT, Junior AS, Cunha KS, Dias EP. Actinic prurigo of the lip: Two case reports. World J Clin Cases. 2014;2:385-90.
  49. Ross G, Foley P, Baker C. Actinic prurigo. Photodermatol Photoimmunol Photomed. 2008;24:272-5.
  50. González-Carrascosa M, De la Cueva DP, Hernanz-Hermosa JM, Chavarría-Mur E. Tratamiento del prurigo actínico con tacrolimus al 0,1%. Med Cutan Ibero Lat Am. 2006;34:233-6.
  51. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: Dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254-73.
  52. Chen M, Doherty SD, Hsu S. Innovative uses of thalidomide. Dermatol Clin. 2010;28:577-86.
  53. Jacobson J. Thalidomide: A remarkable comeback. Expert Opin Pharmacother. 2000;1:849-63.
  54. Estrada I, Garibay-Escobar A, Núñez-Vásquez A, Hojyo-Tomoka T, Vega-Memije E, Cortés-Franco R, et al. Evidence that thalidomide modifies the immune response of patients suffering from actinic prurigo. Int J Dermatol. 2004;43:893-7.
  55. Yong-Gee SA, Muir JB. Long-term thalidomide for actinic prurigo. Australas J Dermatol. 2001;42:281-3.
  56. Umaña A, Gómez A, Durán MM, Porras L. Lymphocyte subtypes and adhesion molecules in actinic prurigo: Observations with cyclosporin A. Int J Dermatol. 2002;41:139-45.
  57. Torres-Álvarez B, Castanedo-Cazares JP, Moncada B. Pentoxifylline in the treatment of actinic prurigo. A preliminary report of 10 patients. Dermatology. 2004;208:198-201.
  58. Grossberg AL. Update on pediatric photosensitivity disorders. Curr Opin Pediatr. 2013;25:474-9.
  59. Paek SY, Lim HW. Chronic actinic dermatitis. Dermatol Clin. 2014;32:355-61.
  60. Tan AW, Lim KS, Theng C, Chong WS. Chronic actinic dermatitis in Asian skin: A Singaporean experience. Photodermatol Photoimmunol Photomed. 2011;27:172-5.
  61. Creamer D, McGregor JM, Hawk JL. Chronic actinic dermatitis occurring in young patients with atopic dermatitis. Br J Dermatol. 1998;139:1112-3.
  62. Meola T, Sánchez M, Lim HW, Buchness MR, Soter NA. Chronic actinic dermatitis associated with human immunodeficiency virus infection. Br J Dermatol. 1997;137:431-6.
  63. Beach RA, Pratt MD. Chronic actinic dermatitis: Clinical cases, diagnostic workup, and therapeutic management. J Cutan Med Surg. 2009;13:121-2.
  64. Menage HD, Harrison GI, Potten CS, Young AR, Hawak JL. The action spectrum for induction of chronic actinic dermatitis is similar to that for sunburn inflammation. Photochem Photobiol. 1995;62:976-8.
  65. Somani VK. Chronic actinic dermatitis—a study of clinical features. Indian J Dermatol Venereol Leprol. 2005;71:409-13.
  66. Pacheco D, Fraga A, Travassos AR, Antunes J, Fretas J, Soares de Almeida L, et al. Actinic reticuloid imitating Sezary syndrome. Acta Dermato Venerol. 2012;21:55-7.
  67. Uetsu N, Okamoto H, Fujii K, Doi R, Horio T. Treatment of chronic actinic dermatitis with tacrolimus ointment. J Am Acad Dermatol. 2002;47:881-4.
  68. Grone D, Kunz M, Zimmermann R, Gross G. Successful treatment of nodular actinic reticuloid with tacrolimus ointment. Dermatology. 2006;212:377-80.
  69. Stinco G, Codutti R, Frattasio A, De Francesco V, Patrone P. Chronic actinic dermatitis treated with cyclosporine A. Eur J Dermatol. 2002;12:455-7.
  70. Murphy GM, Maurice PD, Norris PG, Morris RW, Hawk JL. Azathioprine treatment in chronic actinic dermatitis: A double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol. 1989;121:639-46.
  71. Thomson MA, Stewart DG, Lewis HM. Chronic actinic dermatitis treated with mycophenolate mofetil. Br J Dermatol. 2005;152:784-6.
  72. Safa G, Piéto-LE, Corvaisier C, Hervagault B. Recalcitrant chronic actinic dermatitis treated with low-dose thalidomide. J Am Acad Dermatol. 2005;52:E6.
  73. Rose RF, Goulden V, Wilkinson SM. The spontaneous resolution of photosensitivity and contact allergy in a patient with chronic actinic dermatitis. Photodermatol Photoimmunol Photomed. 2009;25:114-6.
  74. Sugita K, Shimauchi T, Tokura Y. Chronic actinic dermatitis associated with adult T-cell leukemia. J Am Acad Dermatol. 2005;52(Suppl.1):38-40.
  75. Botto NC, Warshaw EM. Solar urticaria. J Am Acad Dermatol. 2008;59:909-20.
  76. Nitiyaram R, Wongpraparut C. Hydroa vaccinifrome and solar urticaria. Dermatol Clin. 2014;32:345-53.
  77. Beattie PE, Dawe RS, Ibbotson SH, Ferquson J. Characteristics and prognosis of idiopathic solar urticaria: A cohort of 87 cases. Arch Dermatol. 2003;139:1149-54.
  78. Beattie PE, Dawe RS, Ibbotson SH, Ferquson J. Co-existence of chronic actinic dermatitis and solar urticaria in three patients. Br J Dermatol. 2004;151:513-5.
  79. Yu RC, King CM, Vickers CF. A case of actinic prurigo and solar urticaria. Clin Exp Dermatol. 1990;15:289-92. 
  80. Dawe RS, Clark C, Ferguson J. Porphyria cutanea tarda presenting as solar urticaria. Br J Dermatol. 1999;141:590-1.
  81. Leenutaphong V, Holzle E, Plewig G. Pathogenesis and classification of solar urticaria: A new concept. J Am Acad Dermatol. 1989;21:237-40.
  82. Reinauer S, Leenutaphong V, Holzle E. Fixed solar urticaria. J Am Acad Dermatol. 1993;29:161-5.
  83. Wessendorf U, Hanneken S, Haust M, Neumann NJ. Fixed solar urticaria with delayed onset. J Am Acad Dermatol. 2009;60:695-7.
  84. Watanabe M, Matsunaga Y, Katayama I. Solar urticaria: A consideration of the mechanism of inhibition spectra. Dermatology. 1999;198:252-5.
  85. Fukunaga A, Horikawa T, Yamamoto A, Yamada Y, Nishigori C. The inhibition spectrum of solar urticaria suppresses the wheal-flare response following intradermal injection with photo-activated autologous serum but not with compound 48/80. Photodermatol Photoimmunol Photomed. 2006;22:129-32.
  86. Neittaanmaki H, Jaaskelainen T, Harvima RJ, Frakj JE. Solar urticaria: Demonstration of histamine release and effective treatment with doxepin. Photodermatol. 1989;6:52-5. 
  87. Tokura Y, Takigawa M, Yamauchi T, Yamada M. Solar urticaria: A case with good therapeutic response to cimetidine. Dermatologica. 1986;173:224-8.
  88. Edstrom DW, Ros AM. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed. 1997;13:61-3.
  89. Pérez A, Woods A, Grattan CE. Methotrexate: A useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol. 2010;162:191-4.
  90. Mitzel-Kaoukhov H, Staubach P, Muller-Brenne T. Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2010;104:253-8.
  91. Correia I, Silva J, Filipe P, Gomes M. Solar urticaria treated successfully with intravenous high-dose immunoglobulin: A case report. Photodermatol Photoimmunol Photomed. 2008;24:330-1.
  92. Adamski H, Bedane C, Bonnevalle A, Thomas P, Peyron JL, Rouchouse B, et al. Solar urticaria treated with intravenous immunoglobulins. J Am Acad Dermatol. 2011;65:336-40.
  93. Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy ClinImmunol. 2010;125:490-1.
  94. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154:177-80.
  95. Masuoka E, Fukunaga A, Kishigami K, Jimbo H, Nishioka M, Uchimura Y, et al. Successful and long-lasting treatment of solar urticaria with ultraviolet A rush hardening therapy. Br J Dermatol. 2012;167:198-201.
  96. Beissert S, Stander H, Schwarz T. UVA rush hardening for the treatment of solar urticaria. J Am Acad Dermatol. 2000;42:1030.
  97. Wolf R, Herzinger T, Grahovac M, Prinz JC. Solar urticaria: Long-term rush hardening by inhibition spectrum narrow-band UVB 311 nm. Clin Exp Dermatol. 2013;38:446-7.
  98. Gupta G, Man I, Kemmett D. Hydroavacciniforme: A clinical and follow-up study of 17 cases. J Am Acad Dermatol. 2000;42:208-13.
  99. Gupta G, Mohamed M, Kemmett D. Familial hydroa vacciniforme. Br J Dermatol. 1999;140:124-6.
  100. Verneuil L, Gouarin S, Comoz F, Aqbalika F, Creveuil C, Varna M, et al. Epstein-Barr virus involvement in the pathogenesis of hydro avacciniforme: An assessment of seven adult patients with long-term follow-up. Br J Dermatol. 2010;163:174-82.
  101. Mendoza N, Diamantis M, Arora A, Bartlett B, Gewirtzman A, Tremaine AM, et al. Mucocutaneous manifestations of Epstein-Barr virus infection. Am J Clin Dermatol. 2008;9:295-305.
  102. Iwatsuki K, Satoh M, Yamamoto T, Oono T, Morizane S, Ohtsuka M, et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol. 2006;142:587-95.
  103. Yamamoto T, Hirai Y, Miyake T, Tamasaki O, Morizane S, Iwatsuki K. Oculo-mucosal and gastrointestinal involvement in Epstein-Barr virus-associated hydroa vacciniforme. Eur J Dermatol. 2012;22:380-3.
  104. Lee HY, Baek JO, Lee JR, Park SH, Jeon IS, Roh JY, et al. Atypical hydroa vacciniforme-like Epstein-Barr virus associated T/NK-cell lymphoproliferative disorder. Am J Dermatopathol. 2012;34:e119-24.
  105. Sonnex TS, Hawk JL. Hydroa vacciniforme: A review of ten cases. Br J Dermatol. 1988;118:101-8.
  106. Huggins RH, Leithauser LA, Eide MJ, Hexsel CL, Jacobsen G Lim HW. Quality of life assessment and disease experience of patient members of a web-based hydroa vacciniforme support group. Photodermatol Photoimmunol Photomed. 2009;25:209-15.
  107. Lysell J, Wiegleb Edstrom D, Linde A, Carlsson G, Malmros-Svennilson J, Westermark A, et al. Antiviral therapy in children with hydroa vacciniforme. Acta Derm Venereol. 2009;89:393-7.
  108. Oono T, Arata J, Masuda T, Ohtsuki Y. Coexistence of hydroa vacciniforme and malignant lymphoma. Arch Dermatol. 1986;122:1306-9.
  109. Quintanilla-Martínez L, Ridaura C, Nagl F, Sáez-de-Ocariz M, Duráan-McKinster C, Ruiz-Maldonado R, et al. Hydroa vacciniforme-like lymphoma: A chronic EBV1 lymphoproliferative disorder with risk to develop a systemic lymphoma. Blood. 2013;122:3101-10.
Female, 66 years old. Vulvar dermatoses of 2 years of evolution.
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 6-7/60-62.
Basal cell carcinoma of the nail unit, a case report
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 57-59.
Discoid lupus in children and adults: ¿What is the difference?
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 51-54.
Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome, about a case
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 47-50.
Immunologically mediated photodermatoses
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 29-44.
Impact of Adalimumab on lymphocyte T infiltration in patiensts with psoriasis.
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 15-18
The birth and development of Bioethics
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 8-12.
Female, 66 years old. Vulvar dermatoses of 2 years of evolution.
Rev Asoc Colomb Dermatol. 24: 1 (Enero-Marzo), 6-7/60-62

PATROCINADORES PRINCIPALES

  • MEDIHEALTH
  • SESDERMA
  • MD FARMACIA MAGISTRAL
  • EPIDERMIQUE
  • ISDIN
  • GALDERMA